Clinical trials: Partial Seizure
Focal Seizure
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
- Trial name
- POWER1 (NCT06999902)
- Testing
- 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
- Where
- 69 sites in United States, Brazil and 5 more
- Volunteers
- 255 people
- Sponsor
- Praxis Precision Medicines
Seizure Disorder
External Trigeminal Nerve Stimulation for Drug Resistent Epilepsy
The purpose of this study is to evaluate the tolerability and safety of the NeuroSigma eTNS system.
- Trial name
- eTNS for DRE (NCT01978470)
- Testing
- External Trigeminal Nerve Stimulation (eTNS)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NeuroSigma, Inc.
Epilepsy
A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
A two arm, randomized, double-blind study comparing zonisamide with placebo. The zonisamide arm will consist of 100 subjects and the placebo arm of 50 subjects.
- Trial name
- NCT01546688
- Testing
- Zonisamide at targeted daily doses of 100-500 mg/day
- Where
- 36 sites in Germany, Hungary and 5 more
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Epilepsy
A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures
The primary purpose of this study is to evaluate the efficacy of perampanel monotherapy measured by the seizure-free rate during the Maintenance Period (24 weeks) of the Treatment Phase in untreated participants with focal onset…
- Trial name
- NCT05533814
- Testing
- Perampanel
- Where
- 10 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- Eisai Korea Inc.
Epilepsy, Motor Partial, Psychogenic Seizures
Detecting PNES With Single-channel sEMG
This is a prospective, comparative, multicenter study of subjects being admitted for standard of care therapy in Epilepsy Monitoring Units in the Veteran's Affair (VA) Medical Centers.
- Trial name
- NCT03313362
- Testing
- SPEAC System, video EEG
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Brain Sentinel
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH
Focal Epilepsy
Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring
ProbCluster trial aims at making the proof of concept of antiseizure efficacy of the old antigout PBN in SC, in which Panx1 involvement is relevant on SC pathophysiology and in which efficient therapies are still lacking.
- Trial name
- PROBCLUSTER (NCT07318870)
- Testing
- Probenecid
- Where
- 2 sites in France
- Volunteers
- 600 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Epilepsy, Partial Seizures
Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures
This study is aimed to evaluate the efficacy, safety and tolerability of oxcarbazepine monotherapy in adults with partial seizures.
- Trial name
- NCT00275925
- Testing
- Oxcarbazepine
- Where
- 7 sites in Russia
- Volunteers
- 80 people
- Sponsor
- Novartis
Epilepsy
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
The primary objective of this study is to assess the efficacy of two doses of Keppra XR compared with a historical control as the placebo, in the monotherapy treatment of partial onset seizures.
- Trial name
- NCT00419094
- Testing
- Keppra XR
- Where
- 45 sites in United States, Mexico and 2 more
- Volunteers
- 228 people
- Sponsor
- UCB Pharma
Focal Onset Seizure, Primary Generalized Epilepsy
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures
- Trial name
- NCT06908356
- Testing
- 30mg PRAX-628
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 50 people
- Sponsor
- Praxis Precision Medicines
Epilepsy, Partial Seizures
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Study A0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either…
- Trial name
- PERIWINKLE (NCT01389596)
- Testing
- Pregabalin add-on therapy
- Where
- 86 sites in United States, Belgium and 16 more
- Volunteers
- 295 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).
- Trial name
- BRITE™ (NCT01339559)
- Testing
- Brivaracetam
- Where
- 184 sites in United States, Austria and 26 more
- Volunteers
- 767 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Epilepsy, Partial Onset Seizures
An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy
The purpose of this study is to evaluate the efficacy of Levetiracetam (LEV) used as monotherapy, with efficacy measured as 6-month seizure freedom at the last evaluated dose in the LEV 1000 mg/day to 2000 mg/day group, in newly…
- Trial name
- NCT01506882
- Testing
- Levetiracetam (LEV)
- Where
- 27 sites in Japan
- Volunteers
- 71 people
- Sponsor
- UCB Japan Co. Ltd.
Focal Onset Seizures
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
- Trial name
- X-TOLE2 (NCT05614063)
- Testing
- XEN1101
- Where
- 125 sites in United States, Argentina and 16 more
- Volunteers
- 380 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Focal Epilepsy
Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)
- Trial name
- POWER2 (NCT07505004)
- Testing
- 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Praxis Precision Medicines
Refractory Epilepsy
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
This is a Phase 2 double-blind, randomized, placebo-controlled study to assess the safety and efficacy of ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC) in subjects with focal…
- Trial name
- NCT04153175
- Testing
- ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)
- Where
- 11 sites in Australia, Israel
- Volunteers
- 30 people
- Sponsor
- Cerebral Therapeutics LLC
Epilepsy With Simple or Complex Partial Onset Seizures
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
- Trial name
- NCT00866775
- Testing
- Eslicarbazepine acetate
- Where
- 106 sites in United States, Canada
- Volunteers
- 193 people
- Sponsor
- Sumitomo Pharma America, Inc.
Partial Onset Seizures
Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)
This study is conducted to evaluate the seizure-free rate of the 26-week Maintenance Period in untreated participants with partial onset seizures (POS).
- Trial name
- NCT03201900
- Testing
- E2007
- Where
- 38 sites in Japan, South Korea
- Volunteers
- 91 people
- Sponsor
- Eisai Co., Ltd.
Epilepsy, Seizures
A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
The purpose of this study is to identify patient characteristics (such as baseline seizure frequency) that may predict effective doses of topiramate using just that one drug (monotherapy) as initial therapy for epilepsy.
- Conditions
- Epilepsy, Seizures, Epilepsies, Partial, Epilepsy, Generalized
- Trial name
- NCT00266604
- Testing
- Topiramate
- Volunteers
- 409 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Partial Seizures
A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures
The primary objective of the present study will be to assess the effectiveness of add-on perampanel in participants with focal seizures in a real-life clinical setting.
- Trial name
- NCT04257604
- Testing
- Perampanel
- Volunteers
- 243 people
- Sponsor
- Eisai Limited